Experts discuss which outcome instruments are most useful in routine clinical practice and address how patients' tendency to underreport disease burden before experiencing effective treatment affects baseline severity assessment and escalation decision-making.
Experts review a phase 2 exploratory analysis of barzolvolimab in CSU, examining off-treatment efficacy at 28 weeks after the final dose, complete response rates, and quality-of-life outcomes among patients who achieved well-controlled disease after 52 weeks of treatment.
Experts review REMIX-1/-2 pooled data on daily Urticaria Activity Score through day 7 and UCT progression through week 52, examining what daily resolution adds to the understanding of BTK inhibition onset and how the trajectory of disease control informs follow-up conversations with patients.
Experts discuss the most clinically meaningful changes in the 2026 international urticaria guideline update, including the expanded step-up therapy framework and the current limitations of biomarkers in routine CSU practice.
